Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

Journal of Clinical Oncology

Volumn 28, Issue 14, 2010, Pages 2323-2330

  Lam, Elaine T ^a   Ringel, Matthew D ^a   Kloos, Richard T ^a   Prior, Thomas W ^a   Knopp, Michael V ^a   Liang, Jiachao ^a   Sammet, Steffen ^a   Hall, Nathan C ^a   Wakely Jr , Paul E ^a   Vasko, Vasyl V ^a   Saji, Motoyasu ^a   Snyder, Pamela J ^a   Wei, Lai ^a   Arbogast, Daria ^a   Collamore, Minden ^a   Wright, John J ^a   Moley, Jeffrey F ^a   Villalona Calero, Miguel A ^a   Shah, Manisha H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PROTEIN RET; SORAFENIB; TUMOR MARKER; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RET PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMNESIA; ANEMIA; ANOREXIA; ARM WEAKNESS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; AUDITORY HALLUCINATION; BLOATING; CHILL; CLINICAL ARTICLE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; FLATULENCE; FLUSHING; GENE MUTATION; GENOTYPE; HAND FOOT SYNDROME; HEADACHE; HEARTBURN; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LIVER FUNCTION TEST; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; METASTASIS; MOUTH PAIN; MUCOSA INFLAMMATION; MUSCLE CRAMP; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; POSITRON EMISSION TOMOGRAPHY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SCALP PRURITUS; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; TACHYCARDIA; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTEADINESS; VISUAL DISORDER; WEIGHT REDUCTION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; MEDULLARY CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PATHOLOGY; THYROID TUMOR; TIME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; BENZENESULFONATES; CARCINOMA, MEDULLARY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; YOUNG ADULT;

EID: 77952468875     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.0068     Document Type: Article

References (31)

1. Hoff AO, Hoff PM: Medullary thyroid carcinoma. Hematol Oncol Clin North Am 21:475-488, 2007 (Pubitemid 46850792)
2. Eng C, Clayton D, Schuffenecker I, et al: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET mutation consortium analysis. JAMA 276:1575-1579, 1996 (Pubitemid 26384740)
3. Brunt LM, Wells SA Jr: Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin North Am 67:263-279, 1987
4. Schlumberger M, Abdelmoumene N, Delisle NJ, et al: Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. Br J Cancer 71:363-365, 1995
5. Hong D, Ye L, Gagel R, et al: Medullary thyroid cancer: Targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7:1001-1006, 2008
6. Cohen EEW, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713, 2008
7. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008
8. Haddad RI, Krebs AD, Vasselli J, et al: A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26:322s, 2008 (supp; abstr 6024)
9. Wells SA, Gosnell JE, Gagel RF, et al: Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. J Clin Oncol 25:303s, 2007 (suppl 18s; abstr 6018)
10. Goulart B, Carr L, Martins RG, et al: Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). J Clin Oncol 26:331s, 2008 (suppl; abstr 6062)
11. Kober F, Hermann M, Handler A, et al: Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 25:617s, 2007 (suppl; abstr 14065)
12. Salgia R, Sherman S, Hong DS, et al: A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 26:XXXX, 2008 (suppl; abstr 3522)
13. Nikiforov YE: Thyroid carcinoma: Molecular pathways and therapeutic targets. Mod Pathol 21:S37-S43, 2008 (suppl)
14. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004 (Pubitemid 39331023)
15. Carlomagno F, Anaganti S, Guida T, et al: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334, 2006 (Pubitemid 43338212)
16. Kloos RT, Ringel MD, Knopp MV, et al: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684, 2009
17. National Cancer Institute: Common Terminology Criteria for Adverse Events, v. 3.0. http://ctep.cancer.gov/reporting/ctc.html
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
20. Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801, 2009
21. Haddad RI, Krebs AD, Vasselli J, et al: A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26:322s, 2008 (suppl; abst 6024)
22. Gehan EA, Tefft MC: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 92:179-181, 2000 (Pubitemid 30099776)
23. Tuma RS: Sometimes size doesn't matter: Reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 98:1272-1274, 2006
24. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006 (Pubitemid 46630627)
25. Schilling T, Bürck J, Sinn HP, et al: Prognostic value of codon 918 (ATG - >ACG) RET protooncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66, 2001
26. Akeno-Stuart N, Croyle M, Knauf JA, et al: The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67:6956-6964, 2007 (Pubitemid 47105543)
27. Salgia R, Sherman S, Hong DS, et al: A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients with advanced malignancies, including patients with medullary thyroid cancer. J Clin Oncol 26:158s, 2008 (suppl; abstr 3522)
28. Kurzrock R, Sherman S, Hong DS, et al: A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients with advanced malignancies, including a subgroup of patients with medullary thyroid cancer. Presented at the 20th Annual European Organisation for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research International Conference on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 21-24, 2008
29. Fassnacht M, Kreissl MC, Weismann D, et al: New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123:117-141, 2009
30. Bunone G, Vigneri P, Mariani L, et al: Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967-1976, 1999
31. Petrangolini G, Cuccuru G, Lanzi C, et al: Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 72:405-414, 2006 (Pubitemid 44061744)